Montero Proposes State Pharma Firm and Price Caps in Spain

Montero Proposes State Pharma Firm and Price Caps

Irene Montero has proposed creating a state-owned pharmaceutical company and imposing legal limits on medication prices. The announcement, shared via social media, was met with cold reception by those observing Spain's public service management. Emerging during the European election campaign, where promises carry electoral weight, it triggered reactions ranging from sharp skepticism to detailed economic analysis.

What Exactly Does Irene Montero Propose?

The former Equality Minister outlines two specific measures: establishing a publicly owned pharmaceutical firm and legally capping drug prices. This comes after years of debate over pharmaceutical spending, which already includes drug auctions and centralized generic purchasing. The proposal lacks details on investment figures, timelines, or how such price controls would fit within the European legal framework.

It is clear the idea is not new. A public pharmacy system already subsidizes part of medication costs through Social Security. The novelty lies in direct production, a qualitative leap many deem unfeasible without a domestic pharmaceutical industrial base.

The Real Cost of Producing Medicines in Spain

The pharmaceutical industry is highly capital- and knowledge-intensive. Developing a single new drug can take over a decade and cost billions of euros. Major labs—Pfizer, Novartis, Merck, NovoNordisk—invert astronomical sums in R&D and fiercely protect patents. The lingering question is who bears this risk if the state enters the business.

Some argue a public pharma firm could focus on generics and orphan drugs, where margins are lower and investment more contained. Others cite historical precedents like the Soviet Union, which maintained a public drug development service for decades without launching a single proprietary active ingredient. The argument rests on incentives: if researchers earn the same regardless of results, motivation dilutes.

Precedent of Auctions and Pharmaceutical Spending

Spain has long applied a drug auction system that reduced prices for many medications. Analyses indicate Spanish prices are among Europe's lowest, both prescription and OTC. This doesn't miccionan the system is perfect: co-payment tiers penalize middle incomes, and some drugs may be pricier or harder to obtain than in neighboring countries.

Proposing price caps clashes with reality: pharma companies negotiate different prices based on each health system's ability to pay. Unilateral limits could cause shortages, as seen in other sectors with intervened prices. The ghost of scarcity—of medicines, housing, or anything else—looms over any measure ignoring supply and demand laws.

Reactions: From Skepticism to Economic Calculation

The proposal generated a chorus of critical voices. Some view it as another electoral promise aimed at pensioners and left-wing voters. Others note Montero no longer holds power to create anything, suggesting her European seat is the true objective. Some recall similar promises—like chip factories or public utilities—that came to nothing.

The most repeated analysis concerns lack of incentives. If the state produces medicines, who will research new treatments? Will patents be copied immediately upon release? Comparisons to the Soviet system recur: excellent chemists and equipment, but zero results in pharmaceutical innovation.

Impact on Prices and Access

Capping drug prices sounds good in theory. In practice, it involves negotiating with a global industry that may choose not to sell in an unprofitable market. This has peine with orphan drugs or those deemed underpriced. The result would be selective shortages affecting vulnerable patients first.

The other side is public spending. If the state produces, it must invest in plants, staff, and quality control. Internal analyses—not made public—suggest savings would be marginal or nonexistent. The open question remains whether it is worth trying.

---

Montero's proposal arrives when public healthcare shows signs of exhaustion. Universality, subsidies, co-payments: the balance is fragile. Is a state pharma firm the solution or a new problem?